ING Groep NV significantly reduced its holding in Thermo Fisher Scientific Inc. (TMO) by 80.0% during the third quarter. This reduction brings ING's current stake in the life sciences company to an estimated $15.53 million. The move comes as Thermo Fisher Scientific announced a substantial $5.00 billion stock buyback program, signaling management's confidence in the company's valuation. Despite ING's divestment, financial analysts generally maintain a 'Moderate Buy' rating for TMO shares. The average target price for TMO stands at $633.68, reflecting a positive outlook from the analytical community. This juxtaposition of institutional selling and a robust buyback initiative creates a mixed sentiment around TMO's near-term performance.
Get AI-powered deep analysis for every story with a paid subscription
Upgrade for Analysis